<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458511432328</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458511432328</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Obstructive sleep apnea is associated with fatigue in multiple sclerosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kaminska</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511432328">1</xref>
<xref ref-type="aff" rid="aff2-1352458511432328">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kimoff</surname><given-names>RJ</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511432328">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Benedetti</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511432328">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Robinson</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff3-1352458511432328">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bar-Or</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff3-1352458511432328">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lapierre</surname><given-names>Y</given-names></name>
<xref ref-type="aff" rid="aff3-1352458511432328">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Schwartzman</surname><given-names>K</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511432328">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Trojan</surname><given-names>DA</given-names></name>
<xref ref-type="aff" rid="aff3-1352458511432328">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458511432328"><label>1</label>Respiratory Division and Sleep Laboratory, McGill University Health Centre, Montreal, Quebec, Canada</aff>
<aff id="aff2-1352458511432328"><label>2</label>Respiratory Division and Respiratory Epidemiology and Clinical Research Unit, McGill University Health Centre, Montreal, Quebec, Canada</aff>
<aff id="aff3-1352458511432328"><label>3</label>Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University Health Centre, Montreal, Quebec, Canada</aff>
<author-notes>
<corresp id="corresp1-1352458511432328">M Kaminska, Royal Victoria Hospital, Respiratory Division, Room L4.08, 687 Pine Avenue West, Montreal, Quebec, Canada H3A 1A1. Email: <email>marta.kaminska@mcgill.ca</email></corresp>
<corresp id="corresp2-1352458511432328">DA Trojan, Montreal Neurological Institute and Hospital, 3801 University Street, Room 138, Montreal, Quebec, Canada H3A 2B4. Email: <email>daria.trojan@mcgill.ca</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>8</issue>
<fpage>1159</fpage>
<lpage>1169</lpage>
<history>
<date date-type="received">
<day>14</day>
<month>6</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>9</day>
<month>9</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>6</day>
<month>11</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1352458511432328">
<title>Background:</title>
<p>Multiple sclerosis (MS) patients often suffer from fatigue.</p>
</sec>
<sec id="section2-1352458511432328">
<title>Objective:</title>
<p>We evaluated the relationship of obstructive sleep apnea (OSA) to fatigue and sleepiness in MS patients.</p>
</sec>
<sec id="section3-1352458511432328">
<title>Methods:</title>
<p>Ambulatory MS patients without known sleep disorders and healthy controls underwent diagnostic polysomnography and a multiple sleep latency test (objective sleepiness measure). Fatigue was measured with the Fatigue Severity Scale (FSS) and the Multidimensional Fatigue Inventory (MFI), and subjective sleepiness by Epworth Sleepiness Scale. Covariates included age, sex, body mass index, Expanded Disability Status Scale (EDSS), depression, pain, nocturia, restless legs syndrome, and medication.</p>
</sec>
<sec id="section4-1352458511432328">
<title>Results:</title>
<p>OSA (apnea–hypopnea index ≥15) was found in 36 of 62 MS subjects and 15 of 32 controls. After adjusting for confounders, severe fatigue (FSS ≥5) and MFI-mental fatigue (&gt;group median) were associated with OSA and respiratory-related arousals in MS, but not control subjects. Subjective and objective sleepiness were not related to OSA in either group. In a multivariate model, variables independently associated with severe fatigue in MS were severe OSA [OR 17.33, 95% CI 2.53–199.84], EDSS [OR 1.88, 95% CI 1.21–3.25], and immunomodulating treatment [OR 0.14, 95% CI 0.023–0.65].</p>
</sec>
<sec id="section5-1352458511432328">
<title>Conclusions:</title>
<p>OSA was frequent in MS and was associated with fatigue but not sleepiness, independent of MS-related disability and other covariates.</p>
</sec>
</abstract>
<kwd-group>
<kwd>fatigue</kwd>
<kwd>multiple sclerosis</kwd>
<kwd>patient-related outcome measures</kwd>
<kwd>polysomnography</kwd>
<kwd>sleep apnea syndromes</kwd>
<kwd>sleep disorders</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section6-1352458511432328" sec-type="intro">
<title>Introduction</title>
<p>Fatigue is a common and disabling symptom of multiple sclerosis (MS).<sup><xref ref-type="bibr" rid="bibr1-1352458511432328">1</xref></sup> It is reported as the main reason for inability of MS patients to sustain full-time employment.<sup><xref ref-type="bibr" rid="bibr2-1352458511432328">2</xref></sup> Fatigue in MS appears to be multifactorial and can result from the disease process itself, ‘primary fatigue’, or from co-existing factors, ‘secondary fatigue’.<sup><xref ref-type="bibr" rid="bibr1-1352458511432328">1</xref></sup> Sleep disturbances may be one contributing factor. Sleep complaints are common in MS, and are exacerbated by MS-related nocturia, pain, spasticity or depression. Subjectively poor sleep quality has been associated with fatigue in MS.<sup><xref ref-type="bibr" rid="bibr3-1352458511432328">3</xref></sup> In the general population, obstructive sleep apnea (OSA) is one of the most frequent sleep disorders, and has been associated primarily with somnolence, but also with fatigue.<sup><xref ref-type="bibr" rid="bibr4-1352458511432328">4</xref><xref ref-type="bibr" rid="bibr5-1352458511432328"/>–<xref ref-type="bibr" rid="bibr6-1352458511432328">6</xref></sup> However, few studies have objectively evaluated sleep disturbances in MS, such as OSA, using polysomnography (PSG). A recent study, using simplified portable PSG, found fatigue scores to be elevated in MS subjects with a range of sleep disorders, with especially high values in those with sleep-disordered breathing,<sup><xref ref-type="bibr" rid="bibr7-1352458511432328">7</xref></sup> suggesting that further characterization of the relationship between OSA and fatigue in MS is warranted.</p>
<p>The main objective of this study was to evaluate the relationship between fatigue or sleepiness and OSA, using complete overnight PSG to measure sleep characteristics, in MS patients compared to normal controls, adjusting for potential confounders. Secondary objectives were to examine the association of OSA-associated sleep fragmentation and intermittent hypoxemia with fatigue, and to identify predictors of severe fatigue in MS.</p>
</sec>
<sec id="section7-1352458511432328" sec-type="methods">
<title>Methods</title>
<sec id="section8-1352458511432328">
<title>Subjects</title>
<p>This was a cross-sectional study, approved by the institutional Ethics Review Board. Participants provided written informed consent. Recruitment occurred between July 2007 and February 2010. MS patients were recruited from the Montreal Neurological Hospital MS Clinic. Inclusion criteria for MS patients were diagnosis of MS (McDonald criteria, 2001),<sup><xref ref-type="bibr" rid="bibr8-1352458511432328">8</xref></sup> Expanded Disability Status Scale (EDSS) score 0 to 7.0 (able to transfer independently for the PSG), relapse-free for at least 30 days prior to screening and during the study, and no chronic steroid treatment (&gt;30 consecutive days) for ≥6 months prior to study entry. Exclusion criteria were age &lt;18 years, pregnancy, cognitive or psychiatric conditions precluding informed consent or compliance with study requirements, presence of significant neurological difficulties (other than MS) or of other significant pulmonary, otorhinological, and medical disorders, major depression within the past year, any value &gt;1.5 times the upper limit or &lt;0.75 times the lower limit (where applicable) of the reference range for any of the screening laboratory determinations (excluding iron profile, vitamin B12 and folate levels), use of medications for restless legs syndrome (RLS) for 4 weeks prior to PSG, active treatment for OSA and forced vital capacity on spirometry &lt;60%. Normal controls without neurological disorders were recruited from dermatology and preoperative clinics (patients and companions), local volunteers (friends of research team members), and from posted library advertisements. They were frequency matched with MS subjects for sex and age (within 5 years except that the oldest control was 78 and the oldest MS patient was 71). Exclusion criteria were as for MS subjects, except that controls did not undergo bloodwork or spirometry.</p>
</sec>
<sec id="section9-1352458511432328">
<title>Study procedures</title>
<p>Subjects underwent three study visits. The first involved a medical history, comprehensive structured sleep assessment (questionnaires), and for MS subjects a physical exam, EDSS calculation, screening blood tests, and spirometry. At the second visit (within 3 months of the first), an interval medical history and study questionnaires were completed, and overnight PSG was performed (acclimatization night). The third visit occurred the following night, when PSG was repeated (diagnostic night), followed by a multiple sleep latency test (MSLT).</p>
</sec>
<sec id="section10-1352458511432328">
<title>Questionnaires</title>
<p>Sleep quality was measured using the Pittsburgh Sleep Quality Index (PSQI).<sup><xref ref-type="bibr" rid="bibr9-1352458511432328">9</xref></sup> A score ≥5 indicates poor sleep quality. A RLS questionnaire was administered using the four diagnostic criteria recommended by the International Restless Legs Syndrome Study Group (IRLSSG).<sup><xref ref-type="bibr" rid="bibr10-1352458511432328">10</xref></sup> The severity of RLS was assessed with the IRLS rating scale.<sup><xref ref-type="bibr" rid="bibr11-1352458511432328">11</xref></sup> A validated narcolepsy questionnaire was administered.<sup><xref ref-type="bibr" rid="bibr12-1352458511432328">12</xref></sup> A non-validated questionnaire was administered for symptoms of parasomnias including REM behavior disorder (RBD). Fatigue was measured with the Fatigue Severity Scale (FSS)<sup><xref ref-type="bibr" rid="bibr13-1352458511432328">13</xref></sup> and the Multidimensional Fatigue Inventory (MFI).<sup><xref ref-type="bibr" rid="bibr14-1352458511432328">14</xref></sup> A score ≥5 on the FSS indicates severe fatigue.<sup><xref ref-type="bibr" rid="bibr15-1352458511432328">15</xref></sup> Subjective daytime sleepiness was assessed with the Epworth Sleepiness Scale (ESS).<sup><xref ref-type="bibr" rid="bibr16-1352458511432328">16</xref></sup> A score &gt;10 indicates excessive sleepiness.<sup><xref ref-type="bibr" rid="bibr16-1352458511432328">16</xref></sup> Symptoms of depression were assessed with the Centre for Epidemiologic Studies – Depression (CES-D) questionnaire.<sup><xref ref-type="bibr" rid="bibr17-1352458511432328">17</xref></sup> The CES-D has been evaluated and recommended as a screening tool for depression in MS.<sup><xref ref-type="bibr" rid="bibr18-1352458511432328">18</xref></sup> A score &gt;16 is the standard cut-off for significant depressed mood. Pain related to MS over the preceding two weeks was evaluated by a visual analog scale: a 10 cm line, lower numbers reflecting less pain. Nocturia was self-reported as the average number of times per night subjects urinate.</p>
</sec>
<sec id="section11-1352458511432328">
<title>Polysomnography</title>
<p>PSG was performed using the Harmonie System (Stellate, Montreal, Qc), with recording of standard electroencephalographic leads (C4/C3/F3/F4/O1/O2/M1/M2), bilateral electrooculogram, chin, anterior tibialis and extensor digitorum electromyograms, airflow via nasal pressure cannula, thoracoabdominal movements via inductive plethysmography (Respitrace Systems, Ardsley, NY), single lead EKG, pulse oximetry, snoring, digital video recording and body position.</p>
<p>Polysomnographic records were scored manually by a single certified polysomnographic technologist with expert physician review, according to AASM criteria<sup><xref ref-type="bibr" rid="bibr19-1352458511432328">19</xref></sup> except that respiratory analysis was based on standard AASM research criteria,<sup><xref ref-type="bibr" rid="bibr20-1352458511432328">20</xref></sup> where an apnea is defined as airflow cessation for ≥10 seconds and a hypopnea as airflow reduction for ≥10 seconds by ≥50%, or associated with arousal or desaturation ≥4%. The number of apneas and hypopneas per hour of sleep constituted the AHI. The number of arousals per hour of sleep associated with either an apnea or hypopnea yielded the Respiratory Arousal Index. An alternative method was also used for analysis, where hypopneas were scored only if associated with an oxygen desaturation ≥4%.<sup><xref ref-type="bibr" rid="bibr19-1352458511432328">19</xref></sup> The number of apneas (with or without desaturation) and hypopneas with ≥4% desaturation per hour of sleep yielded a second index: AHI<sub>D</sub>.</p>
</sec>
<sec id="section12-1352458511432328">
<title>Multiple sleep latency test</title>
<p>The MSLT was conducted as per AASM guidelines<sup><xref ref-type="bibr" rid="bibr21-1352458511432328">21</xref></sup> with four nap opportunities. A mean sleep latency (MSL) was calculated. Severe sleepiness was defined as a MSL ≤ 5 min and moderate sleepiness as a MSL between 5 and 10 min.<sup><xref ref-type="bibr" rid="bibr22-1352458511432328">22</xref></sup></p>
</sec>
<sec id="section13-1352458511432328">
<title>Sleep disorders</title>
<p>Standard criteria were used for the diagnosis of sleep disorders<sup><xref ref-type="bibr" rid="bibr10-1352458511432328">10</xref>,<xref ref-type="bibr" rid="bibr12-1352458511432328">12</xref>,<xref ref-type="bibr" rid="bibr23-1352458511432328">23</xref>,<xref ref-type="bibr" rid="bibr24-1352458511432328">24</xref></sup> (see <xref ref-type="table" rid="table8-1352458511432328">Appendix A</xref>).</p>
</sec>
<sec id="section14-1352458511432328">
<title>Analysis</title>
<p>Fatigue and sleepiness variables were compared with the two-sided <italic>t</italic>-test. Odds ratios (ORs) were obtained by univariate and multivariate logistic regression modeling including both MS and control subjects. To better evaluate predictors of severe fatigue in MS, models were also constructed for MS subjects only. For sleep architecture and sleep disorders, continuous variables were compared using the two-sided <italic>t</italic>-test, and categorical variables using the chi-squared test or the Fisher exact test as appropriate. No correction was made for multiple comparisons, due to the exploratory nature of these secondary analyses. The program R version 2.8.0 was used for analyses.<sup><xref ref-type="bibr" rid="bibr25-1352458511432328">25</xref></sup></p>
</sec>
</sec>
<sec id="section15-1352458511432328" sec-type="results">
<title>Results</title>
<p>Of 275 MS patients approached, 83 were willing to participate, and 65 met inclusion criteria. Two patients did not proceed with the study because of scheduling difficulties. One patient was later excluded due to diagnosis of another CNS disorder. The study population therefore consisted of 62 MS patients and 32 controls. Baseline subject characteristics are given in <xref ref-type="table" rid="table1-1352458511432328">Table 1</xref>. The mean FSS and MFI subscale scores were significantly higher in MS than in control subjects (<italic>p</italic> ≤ 0.0002 for each). Mean subjective sleepiness (ESS) was also greater in MS subjects than in controls (<italic>p</italic> = 0.001), although it remained within the normal range in both groups. Abnormal subjective sleepiness (ESS &gt;10) was more frequent in MS than in control subjects (<italic>p</italic> = 0.03). In the entire study population, the ESS correlated modestly with the FSS (<italic>r</italic> = 0.309, <italic>p</italic> = 0.002), MFI general fatigue (<italic>r</italic> = 0.307, <italic>p</italic> = 0.003), MFI physical functioning (<italic>r</italic> = 0.359, <italic>p</italic> = 0.0004), MFI reduced activity (<italic>r</italic> = 0.340, <italic>p</italic> = 0.0008), MFI mental fatigue (<italic>r</italic> = 0.291, <italic>p</italic> = 0.004) but not significantly with MFI reduced motivation (<italic>r</italic> = 0.190, <italic>p</italic> = 0.07).</p>
<table-wrap id="table1-1352458511432328" position="float">
<label>Table 1.</label>
<caption>
<p>Clinical characteristics of study subjects.</p>
</caption>
<graphic alternate-form-of="table1-1352458511432328" xlink:href="10.1177_1352458511432328-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">MS subjects</th>
<th align="left">Control subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td><italic>N</italic></td>
<td>62</td>
<td>32</td>
</tr>
<tr>
<td>Age (years) Mean (SD)</td>
<td>47.3 (10.4), range 24–71</td>
<td>46.5 (13.4), range 26–78</td>
</tr>
<tr>
<td>Sex – female <italic>n</italic> (%)</td>
<td>45 (73%)</td>
<td>20 (63%)</td>
</tr>
<tr>
<td>BMI (kg/m<sup>2</sup>) Mean (SD)</td>
<td>26.0 (5.1), range (16.1–36.3)</td>
<td>25.9 (6.8), range (16.5–49.4)</td>
</tr>
<tr>
<td>EDSS score (0–10) Mean (SD)</td>
<td>3.6 (1.8), range 1–6.5</td>
<td/>
</tr>
<tr>
<td colspan="3">MS disease type <italic>n</italic> (%)</td>
</tr>
<tr>
<td> Relapsing–remitting</td>
<td>47 (76%)</td>
<td/>
</tr>
<tr>
<td> Secondary progressive</td>
<td>13 (21%)</td>
<td/>
</tr>
<tr>
<td> Progressive relapsing</td>
<td>2 (3%)</td>
<td/>
</tr>
<tr>
<td>Disease duration (y) Mean (SD)</td>
<td>13.4 (8.7), range 0.5 to 35</td>
<td/>
</tr>
<tr>
<td colspan="3">Immuno/chemotherapy within last 6 months <italic>n</italic> (%)</td>
</tr>
<tr>
<td> Any</td>
<td>43 (69%)</td>
<td/>
</tr>
<tr>
<td> Glatiramer acetate</td>
<td>20 (32%)</td>
<td/>
</tr>
<tr>
<td> Interferon beta-1a</td>
<td>7 (11%)</td>
<td/>
</tr>
<tr>
<td> Interferon beta-1b</td>
<td>8 (13%)</td>
<td/>
</tr>
<tr>
<td> Cyclophosphamide</td>
<td>3 (5%)</td>
<td/>
</tr>
<tr>
<td> Mitoxantrone</td>
<td>2 (3%)</td>
<td/>
</tr>
<tr>
<td> Natalizumab</td>
<td>2 (3%)</td>
<td/>
</tr>
<tr>
<td> Fingolimod</td>
<td>1 (2%)</td>
<td/>
</tr>
<tr>
<td colspan="3">Psychotropic or antispasmodic medication <italic>n</italic> (%)</td>
</tr>
<tr>
<td> Antidepressants</td>
<td>21 (34%)</td>
<td>1 (3%)</td>
</tr>
<tr>
<td> Anticonvulsants</td>
<td>18 (29%)</td>
<td>1 (3%)</td>
</tr>
<tr>
<td> Opioids</td>
<td>1 (2%)</td>
<td>0</td>
</tr>
<tr>
<td> Marijuana</td>
<td>1 (2%)</td>
<td>0</td>
</tr>
<tr>
<td> Stimulant</td>
<td>4 (6%)</td>
<td>0</td>
</tr>
<tr>
<td> Antispasmodic</td>
<td>11 (18%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>PSQI Mean (SD)</td>
<td>8.1 (3.9)</td>
<td>4.5 (3.1)</td>
</tr>
<tr>
<td>PSQI &gt; 5 <italic>n</italic> (%)</td>
<td>48 (77%)</td>
<td>9 (28%)</td>
</tr>
<tr>
<td>CES-D Mean (SD)</td>
<td>15.7 (10.4)</td>
<td>6.9 (7.9)</td>
</tr>
<tr>
<td>CES-D &gt; 16 <italic>n</italic> (%)</td>
<td>28 (45%)</td>
<td>3 (9%)</td>
</tr>
<tr>
<td>FSS</td>
<td>5.1 (1.6)</td>
<td>2.7 (1.3)</td>
</tr>
<tr>
<td>FSS ≥ 5 <italic>n</italic> (%)</td>
<td>37 (60%)</td>
<td>4 (13%)</td>
</tr>
<tr>
<td>MFI General fatigue</td>
<td>14.7 (3.5)</td>
<td>7.9 (3.6)</td>
</tr>
<tr>
<td>MFI Physical fatigue</td>
<td>13.8 (3.9)</td>
<td>7.2 (3.8)</td>
</tr>
<tr>
<td>MFI Reduced activity</td>
<td>12.0 (4.5)</td>
<td>7.7 (3.2)</td>
</tr>
<tr>
<td>MFI Reduced motivation</td>
<td>10.2 (3.7)</td>
<td>7.0 (3.8)</td>
</tr>
<tr>
<td>MFI Mental fatigue</td>
<td>12.0 (4.1)</td>
<td>7.2 (3.5)</td>
</tr>
<tr>
<td>ESS</td>
<td>8.4 (4.4)</td>
<td>5.5 (3.6)</td>
</tr>
<tr>
<td>ESS &gt; 10 <italic>n</italic> (%)</td>
<td>21 (34%)</td>
<td>4 (13%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458511432328">
<p><bold>Legend</bold>: BMI, body mass index; EDSS, Expanded Disability Status Scale; PSQI, Pittsburgh Sleep Quality Index; CES-D, Center for Epidemiologic Studies – Depression scale; ESS, Epworth Sleepiness Scale; FSS, Fatigue Severity Scale; MFI, Multidimensional Fatigue Inventory.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section16-1352458511432328">
<title>Sleep disorders</title>
<p><xref ref-type="table" rid="table2-1352458511432328">Table 2</xref> shows sleep disorders identified in MS and control subjects. No significant differences were found between groups in frequency of OSA. Diagnostic criteria for RLS (clinically confirmed) were met more frequently in MS, with a trend toward a higher frequency of severe RLS among MS subjects. The mean (SD) MSL on the MSLT in MS and controls was 11.1 (5.28) and 8.45 (4.65) minutes, respectively (<italic>p</italic> = 0.01). No significant difference was found in the frequency of severe hypersomnolence, based on MSL, between groups, but more controls had any hypersomnolence (<xref ref-type="table" rid="table2-1352458511432328">Table 2</xref>). There was no correlation between the ESS and the MSL in the total study population, or in MS or control groups.</p>
<table-wrap id="table2-1352458511432328" position="float">
<label>Table 2.</label>
<caption>
<p>Sleep Disorders identified in MS and control subjects.</p>
</caption>
<graphic alternate-form-of="table2-1352458511432328" xlink:href="10.1177_1352458511432328-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">MS <italic>N</italic> = 62</th>
<th align="left">Controls <italic>N</italic> = 32</th>
<th align="left">OR <italic>(95% confidence interval)</italic></th>
<th align="left"><italic>p</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>Obstructive sleep apnea (AHI ≥ 15)</td>
<td>36 (58%)</td>
<td>15 (47%)</td>
<td>1.57 (0.67–3.74)</td>
<td>0.39</td>
</tr>
<tr>
<td>RLS (clinically confirmed)</td>
<td>17 (27%)</td>
<td>2 (6%)</td>
<td>5.80 (1.51–38.2)</td>
<td>0.01</td>
</tr>
<tr>
<td>Severe or very severe RLS (IRLS &gt; 20)</td>
<td>12 (19%)</td>
<td>1 (3%)</td>
<td>7.44 (1.36–138.3)</td>
<td>0.054</td>
</tr>
<tr>
<td>REM sleep behaviour disorder</td>
<td>2 (3%)</td>
<td>0</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Narcolepsy</td>
<td>1 (2%)</td>
<td>0</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Severe hypersomnolence MSL ≤ 5 min</td>
<td>11 (18%)</td>
<td>5 (16%)</td>
<td>1.14 (0.37–3.93)</td>
<td>1.0</td>
</tr>
<tr>
<td>Any hypersomnolence MSL ≤ 10 min</td>
<td>28 (45%)</td>
<td>25 (78%)</td>
<td>0.22 (0.079–0.57)</td>
<td>0.002</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1352458511432328">
<p>OR, odds ratios for disorder in MS compared with controls; MSL, mean sleep latency on mean sleep latency test; IRLS, International Restless Legs Syndrome Study Group rating scale; AHI, apnea–hypopnea index; AHI<sub>D</sub> = AHI – desaturations; RLS, restless legs syndrome NA, not available (reliable estimate could not be obtained)..</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section17-1352458511432328">
<title>Sleep architecture</title>
<p>MS subjects had more perturbed sleep architecture than controls (<xref ref-type="table" rid="table3-1352458511432328">Table 3</xref>). Time awake after sleep onset was significantly longer, and the mean Total Arousal Index and Respiratory Arousal Index were higher in the MS group. Sleep efficiency, number of awakenings, proportion of time in non-REM sleep stages, PLM arousal index and PLM sleep index were somewhat worse in the MS group.</p>
<table-wrap id="table3-1352458511432328" position="float">
<label>Table 3.</label>
<caption>
<p>Polysomnography results.</p>
</caption>
<graphic alternate-form-of="table3-1352458511432328" xlink:href="10.1177_1352458511432328-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">MS</th>
<th align="left">Controls</th>
<th align="left"><italic>p</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4"><bold>Sleep architecture</bold></td>
</tr>
<tr>
<td>TST (min)</td>
<td>351.3 (63.5)</td>
<td>357.6 (47.8)</td>
<td>0.59</td>
</tr>
<tr>
<td>Sleep efficiency (%)</td>
<td>80.0 (12.5)</td>
<td>84.4 (10.4)</td>
<td>0.06</td>
</tr>
<tr>
<td>Wake after sleep onset (min)</td>
<td>64.6 (50.7)</td>
<td>40.1 (38.8)</td>
<td>0.01<xref ref-type="table-fn" rid="table-fn3-1352458511432328">*</xref></td>
</tr>
<tr>
<td>Number of awakenings</td>
<td>26.0 (12.6)</td>
<td>21.3 (11.5)</td>
<td>0.07</td>
</tr>
<tr>
<td>Number of stage changes</td>
<td>153.8 (48.1)</td>
<td>141.7 (41.4)</td>
<td>0.21</td>
</tr>
<tr>
<td>Stage N1 (%TST)</td>
<td>10.2 (6.1)</td>
<td>8.3 (4.0)</td>
<td>0.08</td>
</tr>
<tr>
<td>Stage N2 (%TST)</td>
<td>44.2 (9.8)</td>
<td>48.4 (10.7)</td>
<td>0.07</td>
</tr>
<tr>
<td>Stage N3 (%TST)</td>
<td>28.2 (11.9)</td>
<td>24.0 (9.3)</td>
<td>0.06</td>
</tr>
<tr>
<td>Stage R (%TST)</td>
<td>17.4 (6.8)</td>
<td>19.3 (6.4)</td>
<td>0.19</td>
</tr>
<tr>
<td>Total arousal index (/hour)</td>
<td>39.9 (15.9)</td>
<td>32.7 (13.4)</td>
<td>0.02<xref ref-type="table-fn" rid="table-fn3-1352458511432328">*</xref></td>
</tr>
<tr>
<td>Spontaneous arousal index (/hour)</td>
<td>16.2 (7.6)</td>
<td>15.9 (11.5)</td>
<td>0.88</td>
</tr>
<tr>
<td>Respiratory arousal index (/hour)</td>
<td>20.5 (13.2)</td>
<td>15.3 (10.1)</td>
<td>0.04<xref ref-type="table-fn" rid="table-fn3-1352458511432328">*</xref></td>
</tr>
<tr>
<td>PLM arousal index (/hour)</td>
<td>3.1 (6.7)</td>
<td>1.3 (2.5)</td>
<td>0.06</td>
</tr>
<tr>
<td>PLM sleep index (/hour)</td>
<td>17.9 (30.4)</td>
<td>9.2 (14.0)</td>
<td>0.06</td>
</tr>
<tr>
<td>PLM wake index (/hour)</td>
<td>14.8 (26.1)</td>
<td>11.1 (21.2)</td>
<td>0.46</td>
</tr>
<tr>
<td>PLM sleep ≥15 (<italic>n</italic>)</td>
<td>21 (34%)</td>
<td>8 (25%)</td>
<td>0.38</td>
</tr>
<tr>
<td colspan="4"><bold>Respiratory parameters</bold></td>
</tr>
<tr>
<td>Total AHI (/hour) Mean (SD)</td>
<td>20.9 (13.9) range 5.5 to 68.4</td>
<td>18.4 (11.7) range 4.0 to 51.6</td>
<td>0.32</td>
</tr>
<tr>
<td colspan="4">AHI (<italic>n</italic>)</td>
</tr>
<tr>
<td> 5–14.9</td>
<td>26 (42%)</td>
<td>16 (50%)</td>
<td>0.45</td>
</tr>
<tr>
<td> 15–29.9</td>
<td>22 (35%)</td>
<td>10 (31%)</td>
<td>0.68</td>
</tr>
<tr>
<td> ≥ 30</td>
<td>14 (23%)</td>
<td>5 (16%)</td>
<td>0.42</td>
</tr>
<tr>
<td>Central apnea index Mean (SD)</td>
<td>0.4 (0.6)</td>
<td>0.2 (0.4)</td>
<td>0.09</td>
</tr>
<tr>
<td>Obstructive apnea index Mean (SD)</td>
<td>3.3 (7.2)</td>
<td>1.4 (3.5)</td>
<td>0.09</td>
</tr>
<tr>
<td>OH index Mean (SD)</td>
<td>17.0 (9.3)</td>
<td>16.3 (10.1)</td>
<td>0.75</td>
</tr>
<tr>
<td>OH with arousal only index Mean (SD)</td>
<td>14.4 (7.6)</td>
<td>12.5 (8.1)</td>
<td>0.27</td>
</tr>
<tr>
<td>AHI<sub>D</sub> ≥ 5 (<italic>n</italic>)</td>
<td>7 (11%)</td>
<td>5 (16%)</td>
<td>0.53</td>
</tr>
<tr>
<td>Oxygen desaturation<sup><xref ref-type="table-fn" rid="table-fn4-1352458511432328">#</xref></sup> index (ODI) Mean (SD)</td>
<td>3.1 (6.1)</td>
<td>2.5 (4.8)</td>
<td>0.62</td>
</tr>
<tr>
<td>Mean SaO<sub>2</sub> (%) Mean (SD)</td>
<td>95.3 (1.5)</td>
<td>95.4 (1.7)</td>
<td>0.92</td>
</tr>
<tr>
<td>SaO2 &lt; 90% (%TST) Mean (SD)</td>
<td>4.7 (10.4)</td>
<td>3.9 (14.4)</td>
<td>0.63</td>
</tr>
<tr>
<td>Nadir SaO<sub>2</sub> (%) Mean (SD)</td>
<td>86.7 (6.3)</td>
<td>87.6 (8.0)</td>
<td>0.57</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1352458511432328">
<label>*</label>
<p>Statistically significant result.</p>
</fn>
<fn id="table-fn4-1352458511432328">
<label>#</label>
<p>Transient saturation drop by ≥ 4%.</p>
</fn>
<fn id="table-fn5-1352458511432328">
<p>TST, total sleep time; PLM, periodic leg movements; AHI, apnea–hypopnea index; OH, obstructive hypopnea; SaO<sub>2</sub>, hemoglobin oxygen saturation; TST, total sleep time.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section18-1352458511432328">
<title>Sleep-disordered breathing</title>
<p>No differences were found between MS and control groups in the frequency of OSA (<xref ref-type="table" rid="table2-1352458511432328">Table 2</xref>), or in the mean AHI (<xref ref-type="table" rid="table3-1352458511432328">Table 3</xref>). In both groups, the predominant type of event was obstructive hypopnea with arousal only (without ≥4% oxygen desaturation). There were also no differences between groups in oxygen desaturation indices or any other oxygenation measures.</p>
</sec>
<sec id="section19-1352458511432328">
<title>Association between sleep-disordered breathing and fatigue or sleepiness</title>
<p><xref ref-type="table" rid="table4-1352458511432328">Table 4</xref> shows mean values for fatigue and sleepiness measures in MS and control subject subgroups with and without OSA. MS subjects with severe OSA had higher FSS scores than those without OSA. In controls, MFI mental fatigue was reduced in those with OSA.</p>
<table-wrap id="table4-1352458511432328" position="float">
<label>Table 4.</label>
<caption>
<p>Mean values of fatigue, sleepiness and sleep quality variables in MS and control subgroups with and without OSA.</p>
</caption>
<graphic alternate-form-of="table4-1352458511432328" xlink:href="10.1177_1352458511432328-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Mean (SD)</th>
<th align="center" colspan="5">MS<hr/></th>
<th align="center" colspan="5">Control<hr/></th>
</tr>
<tr>
<th/>
<th align="left">A: AHI &lt; 15 <italic>n</italic> = 26</th>
<th align="left">B: AHI ≥ 15 <italic>n</italic> = 36</th>
<th align="left">C: AHI ≥ 30 <italic>n</italic> = 14</th>
<th align="left">p (A vs. B)</th>
<th align="left">p (A vs. C)</th>
<th align="left">D: AHI &lt; 15 <italic>n</italic> = 17</th>
<th align="left">E: AHI ≥ 15 <italic>n</italic> = 15</th>
<th align="left">F: AHI ≥ 30 <italic>n</italic> = 5</th>
<th align="left">p (D vs. E)</th>
<th align="left">p (D vs. F)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSQI</td>
<td>8.23<break/>(3.58)</td>
<td>8.03<break/>(4.11)</td>
<td>9.36<break/>(3.86)</td>
<td>0.84</td>
<td>0.38</td>
<td>4.65<break/>(3.74)</td>
<td>4.27<break/>(2.31)</td>
<td>3.40<break/>(1.95)</td>
<td>0.73</td>
<td>0.34</td>
</tr>
<tr>
<td>FSS</td>
<td>4.83<break/>(1.62)</td>
<td>5.28<break/>(1.53)</td>
<td>5.84<break/>(0.85)</td>
<td>0.27</td>
<td>0.01<xref ref-type="table-fn" rid="table-fn6-1352458511432328">*</xref></td>
<td>2.67<break/>(1.32)</td>
<td>2.67<break/>(1.33)</td>
<td>2.62<break/>(1.33)</td>
<td>0.99</td>
<td>0.94</td>
</tr>
<tr>
<td>MFI General fatigue</td>
<td>14.2<break/>(3.42)</td>
<td>15.0<break/>(3.48)</td>
<td>15.9<break/>(2.84)</td>
<td>0.37</td>
<td>0.10</td>
<td>7.76<break/>(3.47)</td>
<td>8.07<break/>(3.93)</td>
<td>7.6<break/>(2.61)</td>
<td>0.82</td>
<td>0.91</td>
</tr>
<tr>
<td>MFI Physical fatigue</td>
<td>13.1<break/>(4.24)</td>
<td>14.3<break/>(3.53)</td>
<td>14.1<break/>(2.70)</td>
<td>0.25</td>
<td>0.37</td>
<td>6.59<break/>(3.66)</td>
<td>7.80<break/>(4.00)</td>
<td>7.40<break/>(3.85)</td>
<td>0.38</td>
<td>0.69</td>
</tr>
<tr>
<td>MFI Reduced activity</td>
<td>11.3<break/>(4.01)</td>
<td>12.6<break/>(4.74)</td>
<td>13.4<break/>(3.41)</td>
<td>0.22</td>
<td>0.08</td>
<td>6.94<break/>(2.73)</td>
<td>8.53<break/>(3.64)</td>
<td>8.40<break/>(3.78)</td>
<td>0.18</td>
<td>0.46</td>
</tr>
<tr>
<td>MFI Reduced motivation</td>
<td>9.92<break/>(3.72)</td>
<td>10.4<break/>(3.80)</td>
<td>10.7<break/>(3.56)</td>
<td>0.63</td>
<td>0.51</td>
<td>7.06<break/>(4.32)</td>
<td>6.87<break/>(3.14)</td>
<td>6.00<break/>(2.12)</td>
<td>0.89</td>
<td>0.47</td>
</tr>
<tr>
<td>MFI Mental fatigue</td>
<td>12.4<break/>(4.76)</td>
<td>11.8<break/>(3.69)</td>
<td>12.7<break/>(3.36)</td>
<td>0.57</td>
<td>0.80</td>
<td>8.53<break/>(3.76)</td>
<td>5.73<break/>(2.60)</td>
<td>5.20<break/>(1.79)</td>
<td>0.02<xref ref-type="table-fn" rid="table-fn6-1352458511432328">*</xref></td>
<td>0.02<xref ref-type="table-fn" rid="table-fn6-1352458511432328">*</xref></td>
</tr>
<tr>
<td>ESS</td>
<td>8.38<break/>(4.56)</td>
<td>8.42<break/>(4.43)</td>
<td>9.71<break/>(4.07)</td>
<td>0.98</td>
<td>0.35</td>
<td>5.35<break/>(3.33)</td>
<td>5.73<break/>(3.97)</td>
<td>8.6<break/>(5.18)</td>
<td>0.77</td>
<td>0.24</td>
</tr>
<tr>
<td>MSL</td>
<td>11.3<break/>(5.04)</td>
<td>10.9<break/>(5.50)</td>
<td>11.6<break/>(5.59)</td>
<td>0.74</td>
<td>0.91</td>
<td>8.81<break/>(4.52)</td>
<td>8.05<break/>(4.90)</td>
<td>8.06<break/>(4.97)</td>
<td>0.65</td>
<td>0.77</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-1352458511432328">
<label>*</label>
<p>Statistically significant result. OSA, obstructive sleep apnea (apnea–hypopnea index ≥ 15); PSQI, Pittsburgh Sleep Quality Index; ESS, Epworth Sleepiness Scale; FSS, Fatigue Severity Scale; MFI, Multidimensional Fatigue Inventory; MSL, mean sleep latency on mean sleep latency test.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Correlations were assessed between fatigue or sleepiness measures and AHI, AHI<sub>D</sub> or Respiratory Arousal Index. A negative correlation was found between the MSL and AHI<sub>D</sub> (r= -0.208, p=0.04) in the total study population. There were no other significant correlations.</p>
<p>Results from univariate and multivariate logistic regression are shown in <xref ref-type="table" rid="table5-1352458511432328">Table 5</xref>. The AHI showed a significant association, with and without adjustment for confounders, with severe fatigue as measured by FSS and with the mental fatigue component of the MFI in MS but not in control subjects. The ORs represent the association between the dichotomous outcome and an AHI increment of 15 units. For example, compared with an MS subject with an AHI of 5, an MS subject with an AHI of 20 had 2.32 times the odds of having severe fatigue (adjusted). No association was found between the AHI and subjective or objective sleepiness, in either group.</p>
<table-wrap id="table5-1352458511432328" position="float">
<label>Table 5.</label>
<caption>
<p>Logistic regression models for association between measures of fatigue or sleepiness and the apnea–hypopnea index (AHI), the AHI-desaturations (AHI<sub>D</sub>) or the respiratory arousal index.</p>
</caption>
<graphic alternate-form-of="table5-1352458511432328" xlink:href="10.1177_1352458511432328-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Dependent variable</th>
<th align="center" colspan="2">MS<hr/></th>
<th align="center" colspan="2">Controls<hr/></th>
</tr>
<tr>
<th/>
<th align="left">Unadjusted</th>
<th align="left">Adjusted<sup><xref ref-type="table-fn" rid="table-fn8-1352458511432328">$</xref></sup></th>
<th align="left">Unadjusted</th>
<th align="left">Adjusted<sup><xref ref-type="table-fn" rid="table-fn8-1352458511432328">$</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5"><bold>Apnea–hypopnea index (AHI)</bold></td>
</tr>
<tr>
<td>FSS (≥ 5)</td>
<td>2.50 (1.31–5.37)<xref ref-type="table-fn" rid="table-fn9-1352458511432328">*</xref></td>
<td>2.32 (1.15–5.39)<xref ref-type="table-fn" rid="table-fn9-1352458511432328">*</xref></td>
<td>0.40 (0.093–1.13)</td>
<td>1.29 (0.30–4.06)</td>
</tr>
<tr>
<td>MFI general fatigue (&gt; median)</td>
<td>1.57 (0.88–3.06)</td>
<td>1.67 (0.74–4.87)</td>
<td>0.17 (0.03–0.60)<xref ref-type="table-fn" rid="table-fn9-1352458511432328">*</xref></td>
<td>2.02 (0.27–9.87)</td>
</tr>
<tr>
<td>MFI physical fatigue (&gt; median)</td>
<td>2.97 (1.48–6.86)<xref ref-type="table-fn" rid="table-fn9-1352458511432328">*</xref></td>
<td>2.04 (0.99–4.85)</td>
<td>0.54 (0.16–1.31)</td>
<td>2.30 (0.68–8.04)</td>
</tr>
<tr>
<td>MFI mental fatigue (&gt; median)</td>
<td>2.25 (1.21–4.69)<xref ref-type="table-fn" rid="table-fn9-1352458511432328">*</xref></td>
<td>2.58 (1.21–6.56)<xref ref-type="table-fn" rid="table-fn9-1352458511432328">*</xref></td>
<td>0.51 (0.17–1.20)</td>
<td>0.61 (0.14–1.88)</td>
</tr>
<tr>
<td>ESS (&gt; 10)</td>
<td>1.32 (0.78–2.23)</td>
<td>1.13 (0.62–2.05)</td>
<td>0.89 (0.34–1.89)</td>
<td>0.93 (0.30–2.40)</td>
</tr>
<tr>
<td>MSL (&lt; 5)</td>
<td>1.24 (0.65–2.21)</td>
<td>0.96 (0.42–1.90)</td>
<td>1.44 (0.31–3.08)</td>
<td>1.39 (0.47–3.78)</td>
</tr>
<tr>
<td colspan="5"><bold>Respiratory arousal index</bold></td>
</tr>
<tr>
<td>FSS (≥ 5)</td>
<td>3.48 (1.71–8.31)<xref ref-type="table-fn" rid="table-fn9-1352458511432328">*</xref></td>
<td>3.22 (1.46–8.48)<xref ref-type="table-fn" rid="table-fn9-1352458511432328">*</xref></td>
<td>0.42 (0.079–1.40)</td>
<td>1.72 (0.30–7.01)</td>
</tr>
<tr>
<td>MFI general fatigue (&gt; median)</td>
<td>2.06 (1.11–4.27)<xref ref-type="table-fn" rid="table-fn9-1352458511432328">*</xref></td>
<td>2.01 (0.81–6.65)</td>
<td>0.20 (0.033–0.75)<xref ref-type="table-fn" rid="table-fn9-1352458511432328">*</xref></td>
<td>4.79 (0.38–45.4)</td>
</tr>
<tr>
<td>MFI physical fatigue (&gt; median)</td>
<td>2.90 (1.39–7.23)<xref ref-type="table-fn" rid="table-fn9-1352458511432328">*</xref></td>
<td>1.98 (0.92–5.04)</td>
<td>0.14 (0.014–0.68)<xref ref-type="table-fn" rid="table-fn9-1352458511432328">*</xref></td>
<td>0.74 (0.071–4.12)</td>
</tr>
<tr>
<td>MFI mental fatigue (&gt; median)</td>
<td>2.37 (1.28–4.93)<xref ref-type="table-fn" rid="table-fn9-1352458511432328">*</xref></td>
<td>2.71 (1.23–7.13)<xref ref-type="table-fn" rid="table-fn9-1352458511432328">*</xref></td>
<td>0.54 (0.16–1.38)</td>
<td>0.68 (0.15–2.34)</td>
</tr>
<tr>
<td>ESS (&gt; 10)</td>
<td>1.37 (0.79–2.38)</td>
<td>1.29 (0.68–2.46)</td>
<td>0.54 (0.13–1.54)</td>
<td>0.43 (0.081–1.54)</td>
</tr>
<tr>
<td>MSL (&lt; 5)</td>
<td>0.97 (0.47–1.82)</td>
<td>0.71 (0.28–1.54)</td>
<td>0.82 (0.23–2.23)</td>
<td>0.57 (0.11–2.21)</td>
</tr>
<tr>
<td colspan="5"><bold>AHI-desaturations (AHI<sub>D</sub>)</bold></td>
</tr>
<tr>
<td>FSS (≥ 5)</td>
<td>1.62 (0.95–3.68)</td>
<td>1.68 (0.97–3.52)</td>
<td>0.54 (0.10–1.30)</td>
<td>1.82 (0.42–5.46)</td>
</tr>
<tr>
<td>MFI general fatigue (&gt; median)</td>
<td>1.08 (0.67–1.85)</td>
<td>1.03 (0.48–2.22)</td>
<td>0.00 (0.00–0.43)<xref ref-type="table-fn" rid="table-fn9-1352458511432328">*</xref></td>
<td>1.12 (NA–8.74)</td>
</tr>
<tr>
<td>MFI physical fatigue (&gt; median)</td>
<td>1.07 (0.66–1.87)</td>
<td>0.91 (0.48–1.60)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>MFI mental fatigue (&gt; median)</td>
<td>14.56 (2.58–159.9)<xref ref-type="table-fn" rid="table-fn9-1352458511432328">*</xref></td>
<td>46.09 (3.42–1394.2)<xref ref-type="table-fn" rid="table-fn9-1352458511432328">*</xref></td>
<td>0.77 (0.25–1.67)</td>
<td>1.81 (0.55–4.99)</td>
</tr>
<tr>
<td>ESS (&gt; 10)</td>
<td>1.04 (0.57–1.68)</td>
<td>0.96 (0.52–1.65)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>MSL (&lt; 5)</td>
<td>1.28 (0.72–2.11)</td>
<td>1.08 (0.55–1.83)</td>
<td>1.03 (0.26–2.36)</td>
<td>0.68 (0.15–1.92)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-1352458511432328">
<p>Results as adds ratios (ORs) (95% confidence interval) for an AHI and a respiratory arousal index increment of 15 units, and for an AHI<sub>D</sub> increment of 5 units.</p>
</fn>
<fn id="table-fn8-1352458511432328">
<label>$</label>
<p>Models adjusted for age, sex, BMI, disability (Expanded Disability Status Scale; 0 in controls) and depression (Center for Epidemiologic studies – Depression scale).</p>
</fn>
<fn id="table-fn9-1352458511432328">
<label>*</label>
<p>Statistically significant result.</p>
</fn>
<fn id="table-fn10-1352458511432328">
<p>ESS, Epworth Sleepiness Scale; MSL, mean sleep onset latency on test; FSS, Fatigue Severity Scale; MFI, Multidimensional Fatigue Inventory (Reduced Activity and Reduced Motivation subscales omitted - no significant results after correction for confounders); NA, not available (reliable estimate could not be obtained).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p><xref ref-type="table" rid="table5-1352458511432328">Table 5</xref> also shows results for models evaluating the Respiratory Arousal Index and AHI<sub>D</sub>, as predictors of fatigue or sleepiness. The correlation between the Respiratory Arousal Index and AHI<sub>D</sub> was 0.553 (<italic>p</italic> &lt; 0.001), between AHI and AHI<sub>D</sub> 0.619 (<italic>p</italic> &lt; 0.001), and between AHI and the Respiratory Arousal Index 0.877 (<italic>p</italic> &lt; 0.001). AHI<sub>D</sub> was only associated with MFI mental fatigue in the MS group. In univariate analyses, the Respiratory Arousal Index was associated with all measures of fatigue in the MS group, but only with FSS and MFI mental fatigue after adjustment. No associations were found in the control group after adjustment.</p>
</sec>
<sec id="section20-1352458511432328">
<title>Predictors of severe fatigue in MS</title>
<p>MS subjects with (<italic>n</italic> = 37) and without (<italic>n</italic> = 25) severe fatigue (FSS ≥ 5) had a mean AHI of 24.5 (SD 14.8) and 16.2 (SD 10.8), respectively (p = 0.04). Severe OSA was present in 12 (32%) of those with severe fatigue and 2 (8%) of those without severe fatigue (<italic>p</italic> = 0.024). Successive logistic regression models constructed for MS subjects only are shown in <xref ref-type="table" rid="table6-1352458511432328">Table 6</xref>. Models were also constructed including adjustments for each class of psychotropic or antispasmodic medications separately (see <xref ref-type="table" rid="table1-1352458511432328">Table 1</xref>) and combined, RLS severity, pain severity, and self-reported nocturia (number per night). There was no significant effect of these variables on the relationship between severe OSA and severe fatigue (data not shown). In the final model, the only statistically significant predictors of severe fatigue were severe OSA and MS-related disability as reflected by the EDSS, and current immunomodulating treatment, which was inversely associated with severe fatigue (<xref ref-type="table" rid="table7-1352458511432328">Table 7</xref>). Other variables included in the final model were confounders of the relationship between severe OSA and severe fatigue.</p>
<table-wrap id="table6-1352458511432328" position="float">
<label>Table 6.</label>
<caption>
<p>Logistic regression models for association between severe fatigue (FSS &gt; 5) and severe obstructive sleep apnea (AHI ≥ 30) in MS subjects.</p>
</caption>
<graphic alternate-form-of="table6-1352458511432328" xlink:href="10.1177_1352458511432328-table6.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">OR (95% confidence interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Univariate</td>
<td>5.52 (1.32–38.0)<xref ref-type="table-fn" rid="table-fn11-1352458511432328">*</xref></td>
</tr>
<tr>
<td>Including age, sex, BMI</td>
<td>6.63 (1.46–49.3)<xref ref-type="table-fn" rid="table-fn11-1352458511432328">*</xref></td>
</tr>
<tr>
<td>Including age, sex, BMI, EDSS</td>
<td>12.4 (2.24–113.8)<xref ref-type="table-fn" rid="table-fn11-1352458511432328">*</xref></td>
</tr>
<tr>
<td>Including age, sex, BMI, EDSS, CESD</td>
<td>10.4 (1.78–99.1)<xref ref-type="table-fn" rid="table-fn11-1352458511432328">*</xref></td>
</tr>
<tr>
<td>Including age, sex, BMI, EDSS, CESD, immunomodulating treatment in last 6 months</td>
<td>17.3 (2.53–199.8)<xref ref-type="table-fn" rid="table-fn11-1352458511432328">*</xref> <sup><xref ref-type="table-fn" rid="table-fn12-1352458511432328">#</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-1352458511432328">
<label>*</label>
<p>Statistically significant result.</p>
</fn>
<fn id="table-fn12-1352458511432328">
<label>#</label>
<p>Final model.</p>
</fn>
<fn id="table-fn13-1352458511432328">
<p>BMI, body mass index; EDSS, Expanded Disability Status Scale; CESD, Center for Epidemiologic studies – Depression scale.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table7-1352458511432328" position="float">
<label>Table 7.</label>
<caption>
<p>Predictors of severe fatigue in MS subjects.</p>
</caption>
<graphic alternate-form-of="table7-1352458511432328" xlink:href="10.1177_1352458511432328-table7.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Variable</th>
<th align="center" colspan="2">Univariate<hr/></th>
<th align="center" colspan="2">Multivariate<hr/></th>
</tr>
<tr>
<th/>
<th align="left">OR</th>
<th align="left">95% confidence interval</th>
<th align="left">OR</th>
<th align="left">95% confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age<sup><xref ref-type="table-fn" rid="table-fn16-1352458511432328">+</xref></sup></td>
<td>1.01</td>
<td>(0.96–1.07)</td>
<td>0.96</td>
<td>(0.89–1.03)</td>
</tr>
<tr>
<td>BMI<sup><xref ref-type="table-fn" rid="table-fn16-1352458511432328">+</xref></sup></td>
<td>0.96</td>
<td>(0.87–1.06)</td>
<td>0.96</td>
<td>(0.82–1.10)</td>
</tr>
<tr>
<td>Sex (female)</td>
<td>1.05</td>
<td>(0.33–3.25)</td>
<td>2.90</td>
<td>(0.63–15.33)</td>
</tr>
<tr>
<td>EDSS<sup><xref ref-type="table-fn" rid="table-fn16-1352458511432328">+</xref></sup></td>
<td>1.32</td>
<td>(0.97–1.84)</td>
<td>1.88</td>
<td>(1.21–3.25)<xref ref-type="table-fn" rid="table-fn15-1352458511432328">*</xref></td>
</tr>
<tr>
<td>CESD<sup><xref ref-type="table-fn" rid="table-fn16-1352458511432328">+</xref></sup></td>
<td>1.04</td>
<td>(0.99–1.10)</td>
<td>1.03</td>
<td>(0.97–1.11)</td>
</tr>
<tr>
<td>Immunomodulating treatment in last 6 months</td>
<td>0.28</td>
<td>(0.07–0.91)<xref ref-type="table-fn" rid="table-fn15-1352458511432328">*</xref></td>
<td>0.14</td>
<td>(0.023–0.65)<xref ref-type="table-fn" rid="table-fn15-1352458511432328">*</xref></td>
</tr>
<tr>
<td>Severe OSA</td>
<td>5.52</td>
<td>(1.32–38.0)<xref ref-type="table-fn" rid="table-fn15-1352458511432328">*</xref></td>
<td>17.3</td>
<td>(2.53–199.8)<xref ref-type="table-fn" rid="table-fn15-1352458511432328">*</xref></td>
</tr>
<tr>
<td>Pain<sup><xref ref-type="table-fn" rid="table-fn16-1352458511432328">+</xref></sup></td>
<td>1.00</td>
<td>(0.99–1.03)</td>
<td>–</td>
<td/>
</tr>
<tr>
<td>IRLS<sup><xref ref-type="table-fn" rid="table-fn16-1352458511432328">+</xref></sup></td>
<td>1.01</td>
<td>(0.96–1.06)</td>
<td>–</td>
<td/>
</tr>
<tr>
<td>Nocturia<sup><xref ref-type="table-fn" rid="table-fn16-1352458511432328">+</xref></sup></td>
<td>1.04</td>
<td>(0.67–1.67)</td>
<td>–</td>
<td/>
</tr>
<tr>
<td>Psychotropic or antispasmodic treatment</td>
<td>2.33</td>
<td>(0.83–6.83)</td>
<td>–</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn14-1352458511432328">
<p>Univariate odds ratios (ORs) for all variables studied, and multivariate OR for variables included in the final model.</p>
</fn>
<fn id="table-fn15-1352458511432328">
<label>*</label>
<p>Statistically significant result.</p>
</fn>
<fn id="table-fn16-1352458511432328">
<label>+</label>
<p>ORs for change in variable of 1 unit. Pain measured by visual analog scale; nocturia is self-reported as the number of times per night.</p>
</fn>
<fn id="table-fn17-1352458511432328">
<p>BMI, body mass index; EDSS, Expanded Disability Status Scale; CESD, Center for Epidemiologic studies – Depression scale; IRLS, International Restless Legs Syndrome Study Group rating scale.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section21-1352458511432328" sec-type="discussion">
<title>Discussion</title>
<p>We evaluated sleep disorders in MS with an emphasis on OSA and its relationship with fatigue and sleepiness. We found a significant association between OSA and severe fatigue, as measured by the FSS, in MS but not in control subjects. Severe OSA (AHI ≥ 30) was most clearly associated with severe fatigue. Specifically, the mean FSS was significantly higher in MS subjects with severe OSA as compared with those without OSA. Furthermore, after adjusting for important confounders, severe fatigue was strongly associated with severe OSA in MS subjects as compared with those with an AHI &lt; 30.</p>
<p>MFI subscales were not significantly different between MS OSA and non-OSA groups, but general fatigue and reduced activity trended toward higher values in those with severe OSA. In multivariate analysis, the MFI mental fatigue subscale was significantly associated with OSA in MS, but not control subjects. Of note, in contrast to the FSS, the MFI does not have a clearly established threshold for severe fatigue.<sup><xref ref-type="bibr" rid="bibr13-1352458511432328">13</xref>,<xref ref-type="bibr" rid="bibr14-1352458511432328">14</xref></sup> It is possible that the group median which we used as the basis for dichotomization was not the optimal cut-off for biological significance.</p>
<p>OSA is characterized by intermittent hypoxemia and respiratory-related sleep fragmentation. We found no association between severe fatigue and AHI<sub>D</sub>, which reflects intermittent hypoxemia. Conversely, there was a strong association between severe fatigue and the respiratory arousal index in the MS group (<xref ref-type="table" rid="table5-1352458511432328">Table 5</xref>), suggesting that it is respiratory-related sleep fragmentation rather than intermittent hypoxemia which is primarily responsible for the increased fatigue. A recent study by Veauthier et al. has also found high fatigue scores in MS patients with sleep-disordered breathing,<sup><xref ref-type="bibr" rid="bibr7-1352458511432328">7</xref></sup> but this was not further characterized or adjusted for confounders. Our results provide novel insights through a detailed description of OSA in MS, including sleep fragmentation and intermittent hypoxemia, and its association with fatigue, and adjustment for confounders. An association between fatigue and OSA has also been reported in the general population, particularly the upper airway resistance syndrome, which is characterized by respiratory-related sleep fragmentation without oxygen desaturation.<sup><xref ref-type="bibr" rid="bibr4-1352458511432328">4</xref><xref ref-type="bibr" rid="bibr5-1352458511432328"/>–<xref ref-type="bibr" rid="bibr6-1352458511432328">6</xref></sup> Treatment with continuous positive airway pressure (CPAP) improves fatigue in OSA patients.<sup><xref ref-type="bibr" rid="bibr26-1352458511432328">26</xref></sup> While we did not observe an association between fatigue and OSA in our control group, this may have been due to lack of statistical power, given the relatively small number of controls and the chance recruitment of subjects with very low fatigue scores.</p>
<p>OSA could worsen fatigue through a variety of mechanisms. Fatigue in MS is associated with reduced cerebral glucose metabolism<sup><xref ref-type="bibr" rid="bibr27-1352458511432328">27</xref></sup> and hypoperfusion of specific gray matter regions,<sup><xref ref-type="bibr" rid="bibr28-1352458511432328">28</xref></sup> which is thought to represent neuronal loss or axonal degeneration. OSA also causes gray matter abnormalities<sup><xref ref-type="bibr" rid="bibr29-1352458511432328">29</xref>,<xref ref-type="bibr" rid="bibr30-1352458511432328">30</xref></sup> that could exacerbate the MS- related changes. Fatigue in MS has also been related to compensatory excessive activation of normal CNS areas.<sup><xref ref-type="bibr" rid="bibr31-1352458511432328">31</xref></sup> A similar phenomenon has been described in OSA.<sup><xref ref-type="bibr" rid="bibr32-1352458511432328">32</xref></sup> Fatigue has also been linked with inflammation in MS<sup><xref ref-type="bibr" rid="bibr33-1352458511432328">33</xref></sup> and OSA may increase systemic inflammation.<sup><xref ref-type="bibr" rid="bibr34-1352458511432328">34</xref></sup> In addition, sympathetic hyperactivity may contribute to chronic fatigue syndrome pathogenesis<sup><xref ref-type="bibr" rid="bibr35-1352458511432328">35</xref></sup> and OSA is associated with chronic sympathetic overactivity<sup><xref ref-type="bibr" rid="bibr36-1352458511432328">36</xref></sup> which could exacerbate fatigue in MS.</p>
<p>OSA was frequent in both MS and control subjects with no significant difference between groups. The apparent high frequency of OSA in both groups is likely due to several factors. It is possible that our population was subject to selection bias, with greater participation of individuals who had already noted symptoms of OSA. However, a key factor explaining the prevalence of OSA in this study is that the definition of respiratory events on PSG affects the measured prevalence of OSA. The AHI is composed of apneas and hypopneas, and the majority of observed events were hypopneas in both MS and control groups. Several definitions of hypopnea have been applied in the literature, and more inclusive definitions can substantially increase the AHI and therefore the number of ‘affected individuals’.<sup><xref ref-type="bibr" rid="bibr37-1352458511432328">37</xref><xref ref-type="bibr" rid="bibr38-1352458511432328"/>-<xref ref-type="bibr" rid="bibr39-1352458511432328">39</xref></sup> In this study we have used standard recommended research scoring criteria,<sup><xref ref-type="bibr" rid="bibr20-1352458511432328">20</xref></sup> which are inclusive and capture respiratory events associated with either oxygen desaturation, cortical arousal, both or neither. We have also calculated the AHI<sub>D</sub>, which requires oxygen desaturation, and corresponds to the measure used in early population studies of OSA. We found an AHI<sub>D</sub> ≥ 5 in 11% and 16% of MS and control subjects, similar to the previously reported population prevalence of AHI<sub>D</sub> ≥ 5 in 9% of women and 24% of men in the Wisconsin Sleep Cohort,<sup><xref ref-type="bibr" rid="bibr40-1352458511432328">40</xref></sup> the most widely cited population-based OSA study. ICSD-II<sup><xref ref-type="bibr" rid="bibr24-1352458511432328">24</xref></sup> defines OSA as either an AHI ≥ 5 with symptoms or an AHI ≥ 15 even in the absence of symptoms. We have used the latter in this study. While our results do not establish an MS prevalence of OSA in comparison to the general population, the proportion of OSA cases found and the strong association with fatigue emphasize this comordibity as a non-trivial issue in MS. Furthermore, this association supports the inclusive definition of hypopnea used in this analysis.</p>
<p>Despite a similar mean total AHI, MS subjects had a higher mean respiratory arousal index than controls, suggesting that respiratory disturbances in MS result in more sleep fragmentation. Likely as a result of MS-related factors impairing sleep quality,<sup><xref ref-type="bibr" rid="bibr41-1352458511432328">41</xref>,<xref ref-type="bibr" rid="bibr42-1352458511432328">42</xref></sup> MS subjects had generally more fragmented sleep than controls. This might be associated with a lower arousal threshold, such that respiratory events would be more likely to provoke arousal in an MS subject. Sleep fragmentation could also be a factor in OSA pathogenesis in MS. Sleep–wake instability caused by MS-related factors would be expected to induce respiratory instability, resulting in a periodic breathing pattern that may normally be observed transiently at sleep onset. A low arousal threshold may trigger another arousal and a self-perpetuating sequence of hypopneas with arousals, resulting in overt sleep-disordered breathing.<sup><xref ref-type="bibr" rid="bibr43-1352458511432328">43</xref></sup></p>
<p>We did not find subjective sleepiness (ESS) to be associated with OSA in either MS or control groups. This is consistent with the literature, where an association between ESS and AHI has often not been found,<sup><xref ref-type="bibr" rid="bibr44-1352458511432328">44</xref><xref ref-type="bibr" rid="bibr45-1352458511432328"/>–<xref ref-type="bibr" rid="bibr46-1352458511432328">46</xref></sup> although ESS scores decrease overall with treatment of OSA.<sup><xref ref-type="bibr" rid="bibr47-1352458511432328">47</xref></sup> The ESS is widely used as a measure of sleepiness but correlates poorly in the general population with objective measures such as MSL.<sup><xref ref-type="bibr" rid="bibr46-1352458511432328">46</xref>,<xref ref-type="bibr" rid="bibr48-1352458511432328">48</xref><xref ref-type="bibr" rid="bibr49-1352458511432328"/>–<xref ref-type="bibr" rid="bibr50-1352458511432328">50</xref></sup> We found no correlation between ESS and MSL in our data, but significant correlations between ESS and measures of fatigue. This finding has also been reported by others in various patients groups.<sup><xref ref-type="bibr" rid="bibr51-1352458511432328">51</xref><xref ref-type="bibr" rid="bibr52-1352458511432328"/>–<xref ref-type="bibr" rid="bibr53-1352458511432328">53</xref></sup> It suggests that subjective sleepiness as measured by the ESS is in fact a construct more closely related to fatigue than to objectively measured hypersomnolence.</p>
<p>While the ESS was not associated with any OSA variables, the MSL negatively correlated with the AHI<sub>D</sub> in our entire population. Separate correlations for MS and control groups as well as logistic regression analyses were less informative in this respect, likely due to the low frequency of intermittent hypoxemia in our study population. A shorter MSL has previously been associated with worse nocturnal oxygenation,<sup><xref ref-type="bibr" rid="bibr44-1352458511432328">44</xref>,<xref ref-type="bibr" rid="bibr54-1352458511432328">54</xref></sup> but also respiratory-related arousals.<sup><xref ref-type="bibr" rid="bibr50-1352458511432328">50</xref>,<xref ref-type="bibr" rid="bibr55-1352458511432328">55</xref></sup> Animal data suggest that intermittent hypoxemia can cause oxidative brain injury resulting in hypersomnolence.<sup><xref ref-type="bibr" rid="bibr56-1352458511432328">56</xref></sup></p>
<p>Mild hypersomnolence on the MSLT occurred more frequently in control than MS subjects. This impaired ability to fall asleep during a daytime nap in MS was present in the face of greater nocturnal sleep fragmentation compared with controls. A possible explanation is that MS-related factors such as discomfort related to spasticity or sensory-motor dysfunction may impair both daytime naps and nocturnal sleep consolidation. MS subjects are also more likely to experience psychological distress, which has been found to prolong MSL.<sup><xref ref-type="bibr" rid="bibr57-1352458511432328">57</xref></sup> On the other hand, the shorter than expected MSL in controls may result from the study protocol itself, which created mild sleep deprivation; the effect of two consecutive nights in the PSG laboratory on MSL in healthy individuals has not been well studied.</p>
<p>In addition to severe OSA, our final model identified two other significant predictors of severe fatigue in MS. MS disability (EDSS) was a significant albeit modest contributor to severe fatigue. Conflicting reports on the relationship between fatigue and disability in MS have been published,<sup><xref ref-type="bibr" rid="bibr3-1352458511432328">3</xref>,<xref ref-type="bibr" rid="bibr58-1352458511432328">58</xref><xref ref-type="bibr" rid="bibr59-1352458511432328"/>–<xref ref-type="bibr" rid="bibr60-1352458511432328">60</xref></sup> but physical fatigue specifically appears to be related to the EDSS.<sup><xref ref-type="bibr" rid="bibr3-1352458511432328">3</xref>,<xref ref-type="bibr" rid="bibr61-1352458511432328">61</xref></sup> The second factor was recent immunomodulating treatment, which was associated with less severe fatigue. Although some immunomodulating therapies may themselves produce fatigue, the literature supports an overall beneficial effect on fatigue.<sup><xref ref-type="bibr" rid="bibr15-1352458511432328">15</xref>,<xref ref-type="bibr" rid="bibr62-1352458511432328">62</xref></sup></p>
<p>In summary, we have demonstrated a strong association in MS between severe fatigue and severe OSA, particularly respiratory-related sleep fragmentation. Although causality cannot be inferred from this cross-sectional study, there are plausible biological mechanisms by which OSA and fatigue may interact in MS. The magnitude of the association between severe fatigue and severe OSA, and the high frequency of severe OSA in fatigued MS subjects provide a strong rationale for further investigations to evaluate the effects of OSA treatment on fatigue and quality of life in MS.</p>
</sec>
</body>
<back>
<app-group>
<table-wrap id="table8-1352458511432328" position="float">
<label>Appendix A:</label>
<caption>
<p>Sleep disorders diagnostic criteria</p>
</caption>
<graphic alternate-form-of="table8-1352458511432328" xlink:href="10.1177_1352458511432328-table8.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>Obstructive sleep apnea (OSA)</td>
<td><list list-type="bullet">
<list-item><p>Apnea–hypopnea index ≥ 15</p></list-item>
</list></td>
</tr>
<tr>
<td>Restless legs syndrome (RLS)</td>
<td><list list-type="bullet">
<list-item><p>Unpleasant sensations in the legs, combined with an urge to move the legs;</p></list-item>
<list-item><p>Sensations occurring mainly at rest and improving with movement;</p></list-item>
<list-item><p>Sensations worse in the evening or at night.</p></list-item>
</list></td>
</tr>
<tr>
<td>Narcolepsy</td>
<td><list list-type="bullet">
<list-item><p>Excessive daytime sleepiness occurring almost daily for at least 3 months,</p></list-item>
<list-item><p>Mean sleep latency (MSL) ≤ 8 minutes on MSL test, with ≥ 2 sleep-onset REM periods (SOREMP’s), after ≥ 6 hours total sleep time on previous night’s PSG.</p></list-item>
</list></td>
</tr>
<tr>
<td/>
<td>Without cataplexy: absence of typical cataplexy.</td>
</tr>
<tr>
<td/>
<td>With cataplexy: presence of typical cataplexy.</td>
</tr>
<tr>
<td>Rapid Eye Movement (REM) Behavior Disorder</td>
<td><list list-type="bullet">
<list-item><p>Absence of REM atonia on PSG (persistence of tonic or increased phasic EMG activity during REM),</p></list-item>
<list-item><p>Presence of one or more of:
<list list-type="bullet">
<list-item><p>history of sleep-related injurious, or potentially injurious or disruptive behaviors;</p></list-item>
<list-item><p>abnormal behaviors during REM documented at PSG, and</p></list-item>
</list></p></list-item>
<list-item><p>Absence of epileptiform activity during REM sleep.</p></list-item>
</list></td>
</tr>
</tbody>
</table>
</table-wrap>
</app-group>
<ack>
<p>We would like to thanks the following contributors: we thank Dr Isabelle Côté who confirmed the subjects’ sleep diagnoses and initiated their treatment, and helped with data management; Gustavo Torres and Allen Olha for conducting the polysomnographies and Allen Olha also for diligently scoring them all; Dr Deborah Weiss and Mauro Cardoso who helped with data management; and Dr Deborah Da Costa and Adriana Venturini for their input in study planning. Lastly, we thank Dr Michel Aube, Dr Jack Antel, and Dr Douglas Arnold for referring patients for the study.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>Multiple Sclerosis Society of Canada, Fonds de Recherche en Santé du Québec, Montreal Neurological Institute.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458511432328">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kos</surname><given-names>D</given-names></name>
<name><surname>Kerckhofs</surname><given-names>E</given-names></name>
<name><surname>Nagels</surname><given-names>G</given-names></name>
<name><surname>D’hooghe</surname><given-names>MB</given-names></name>
<name><surname>Ilsbroukx</surname><given-names>S</given-names></name>
</person-group>. <article-title>Origin of fatigue in multiple sclerosis: review of the literature</article-title>. <source>Neurorehabil Neural Repair</source> <year>2008</year>; <volume>22</volume>: <fpage>91</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr2-1352458511432328">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jongbloed</surname><given-names>L</given-names></name>
</person-group>. <article-title>Disability incomes: The experiences of women with multiple sclerosis</article-title>. <source>Can J Occupat Therapy</source> <year>1998</year>; <volume>65</volume>: <fpage>193</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr3-1352458511432328">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trojan</surname><given-names>DA</given-names></name>
<name><surname>Arnold</surname><given-names>D</given-names></name>
<name><surname>Collet</surname><given-names>JP</given-names></name>
<etal/>
</person-group>. <article-title>Fatigue in multiple sclerosis: association with disease-related, behavioural and psychosocial factors</article-title>. <source>Mult Scler</source> <year>2007</year>; <volume>13</volume>: <fpage>985</fpage>–<lpage>995</lpage>.</citation>
</ref>
<ref id="bibr4-1352458511432328">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chervin</surname><given-names>RD</given-names></name>
</person-group>. <article-title>Sleepiness, fatigue, tiredness, and lack of energy in obstructive sleep apnea</article-title>. <source>Chest</source> <year>2000</year>; <volume>118</volume>: <fpage>372</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr5-1352458511432328">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guilleminault</surname><given-names>C</given-names></name>
<name><surname>Lopes</surname><given-names>MC</given-names></name>
<name><surname>Hagen</surname><given-names>CC</given-names></name>
<name><surname>da</surname><given-names>RA</given-names></name>
</person-group>. <article-title>The cyclic alternating pattern demonstrates increased sleep instability and correlates with fatigue and sleepiness in adults with upper airway resistance syndrome</article-title>. <source>Sleep</source> <year>2007</year>; <volume>30</volume>: <fpage>641</fpage>–<lpage>647</lpage>.</citation>
</ref>
<ref id="bibr6-1352458511432328">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yue</surname><given-names>HJ</given-names></name>
<name><surname>Bardwell</surname><given-names>W</given-names></name>
<name><surname>ncoli-Israel</surname><given-names>S</given-names></name>
<name><surname>Loredo</surname><given-names>JS</given-names></name>
<name><surname>Dimsdale</surname><given-names>JE</given-names></name>
</person-group>. <article-title>Arousal frequency is associated with increased fatigue in obstructive sleep apnea</article-title>. <source>Sleep Breath</source> <year>2009</year>; <comment>in press</comment>.</citation>
</ref>
<ref id="bibr7-1352458511432328">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Veauthier</surname><given-names>C</given-names></name>
<name><surname>Radbruch</surname><given-names>H</given-names></name>
<name><surname>Gaede</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Fatigue in multiple sclerosis is closely related to sleep disorders: a polysomnographic cross-sectional study</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>613</fpage>–<lpage>622</lpage>.</citation>
</ref>
<ref id="bibr8-1352458511432328">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McDonald</surname><given-names>WI</given-names></name>
<name><surname>Compston</surname><given-names>A</given-names></name>
<name><surname>Edan</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis</article-title>. <source>Ann Neurol</source> <year>2001</year>; <volume>50</volume>: <fpage>121</fpage>–<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr9-1352458511432328">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buysse</surname><given-names>DJ</given-names></name>
<name><surname>Reynolds</surname><given-names>CF</given-names><suffix>III</suffix></name>
<name><surname>Monk</surname><given-names>TH</given-names></name>
<name><surname>Berman</surname><given-names>SR</given-names></name>
<name><surname>Kupfer</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research</article-title>. <source>Psychiatry Res</source> <year>1989</year>; <volume>28</volume>: <fpage>193</fpage>–<lpage>213</lpage>.</citation>
</ref>
<ref id="bibr10-1352458511432328">
<label>10.</label>
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Allen</surname><given-names>RP</given-names></name>
<name><surname>Picchietti</surname><given-names>D</given-names></name>
<name><surname>Hening</surname><given-names>WA</given-names></name>
<name><surname>Trenkwalder</surname><given-names>C</given-names></name>
<name><surname>Walters</surname><given-names>AS</given-names></name>
<name><surname>Montplaisi</surname><given-names>J</given-names></name>
</person-group>. <article-title>Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health</article-title>. <conf-name>Sleep Med</conf-name> <conf-date>2003</conf-date>; <volume>4</volume>: <fpage>101</fpage>–<lpage>119</lpage>.</citation>
</ref>
<ref id="bibr11-1352458511432328">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walters</surname><given-names>AS</given-names></name>
<name><surname>LeBrocq</surname><given-names>C</given-names></name>
<name><surname>Dhar</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome</article-title>. <source>Sleep Med</source> <year>2003</year>; <volume>4</volume>: <fpage>121</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr12-1352458511432328">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hublin</surname><given-names>C</given-names></name>
<name><surname>Kaprio</surname><given-names>J</given-names></name>
<name><surname>Partinen</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort</article-title>. <source>Ann Neurol</source> <year>1994</year>; <volume>35</volume>: <fpage>709</fpage>–<lpage>716</lpage>.</citation>
</ref>
<ref id="bibr13-1352458511432328">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krupp</surname><given-names>LB</given-names></name>
<name><surname>LaRocca</surname><given-names>NG</given-names></name>
<name><surname>Muir-Nash</surname><given-names>J</given-names></name>
<name><surname>Steinberg</surname><given-names>AD</given-names></name>
</person-group>. <article-title>The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus</article-title>. <source>Arch Neurol</source> <year>1989</year>; <volume>46</volume>: <fpage>1121</fpage>–<lpage>1123</lpage>.</citation>
</ref>
<ref id="bibr14-1352458511432328">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smets</surname><given-names>EM</given-names></name>
<name><surname>Garssen</surname><given-names>B</given-names></name>
<name><surname>Cull</surname><given-names>A</given-names></name>
<name><surname>de Haes</surname><given-names>JC</given-names></name>
</person-group>. <article-title>Application of the multidimensional fatigue inventory (MFI-20) in cancer patients receiving radiotherapy</article-title>. <source>Br J Cancer</source> <year>1996</year>; <volume>73</volume>: <fpage>241</fpage>–<lpage>245</lpage>.</citation>
</ref>
<ref id="bibr15-1352458511432328">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Putzki</surname><given-names>N</given-names></name>
<name><surname>Katsarava</surname><given-names>Z</given-names></name>
<name><surname>Vago</surname><given-names>S</given-names></name>
<name><surname>Diener</surname><given-names>HC</given-names></name>
<name><surname>Limmroth</surname><given-names>V</given-names></name>
</person-group>. <article-title>Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients</article-title>. <source>Eur Neurol</source> <year>2008</year>; <volume>59</volume>: <fpage>136</fpage>–<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr16-1352458511432328">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johns</surname><given-names>MW</given-names></name>
</person-group>. <article-title>A new method for measuring daytime sleepiness: the Epworth sleepiness scale</article-title>. <source>Sleep</source> <year>1991</year>; <volume>14</volume>: <fpage>540</fpage>–<lpage>545</lpage>.</citation>
</ref>
<ref id="bibr17-1352458511432328">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Radloff</surname><given-names>LS</given-names></name>
</person-group>. <article-title>The CES-D Scale: a self-report depression scale for research in the general population</article-title>. <source>Appl Psychol Measure</source> <year>1977</year>; <volume>1</volume>: <fpage>385</fpage>–<lpage>401</lpage>.</citation>
</ref>
<ref id="bibr18-1352458511432328">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Verdier-Taillefer</surname><given-names>MH</given-names></name>
<name><surname>Gourlet</surname><given-names>V</given-names></name>
<name><surname>Fuhrer</surname><given-names>R</given-names></name>
<name><surname>Alperovitch</surname><given-names>A</given-names></name>
</person-group>. <article-title>Psychometric properties of the Center for Epidemiologic Studies-Depression scale in multiple sclerosis</article-title>. <source>Neuroepidemiology</source> <year>2001</year>; <volume>20</volume>: <fpage>262</fpage>–<lpage>267</lpage>.</citation>
</ref>
<ref id="bibr19-1352458511432328">
<label>19.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Iber</surname><given-names>C</given-names></name>
<name><surname>Ancoli-Israel</surname><given-names>S</given-names></name>
<name><surname>Chesson</surname><given-names>A</given-names></name>
<name><surname>Quan</surname><given-names>S</given-names></name>
</person-group>. <source>The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications</source>. <edition>1st ed.</edition> <publisher-loc>Westchester, IL</publisher-loc>: <publisher-name>AASM</publisher-name>, <year>2007</year>.</citation>
</ref>
<ref id="bibr20-1352458511432328">
<label>20.</label>
<citation citation-type="journal">
<collab>American Academy of Sleep Medicine Task Force</collab>. <article-title>Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research</article-title>. <source>Sleep</source> <year>1999</year>; <volume>22</volume>: <fpage>667</fpage>–<lpage>689</lpage>.</citation>
</ref>
<ref id="bibr21-1352458511432328">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carskadon</surname><given-names>MA</given-names></name>
<name><surname>Dement</surname><given-names>WC</given-names></name>
<name><surname>Mitler</surname><given-names>MM</given-names></name>
<name><surname>Roth</surname><given-names>T</given-names></name>
<name><surname>Westbrook</surname><given-names>PR</given-names></name>
<name><surname>Keenan</surname><given-names>S</given-names></name>
</person-group>. <article-title>Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness</article-title>. <source>Sleep</source> <year>1986</year>; <volume>9</volume>: <fpage>519</fpage>–<lpage>524</lpage>.</citation>
</ref>
<ref id="bibr22-1352458511432328">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arand</surname><given-names>D</given-names></name>
<name><surname>Bonnet</surname><given-names>M</given-names></name>
<name><surname>Hurwitz</surname><given-names>T</given-names></name>
<name><surname>Mitler</surname><given-names>M</given-names></name>
<name><surname>Rosa</surname><given-names>R</given-names></name>
<name><surname>Sangal</surname><given-names>RB</given-names></name>
</person-group>. <article-title>The clinical use of the MSLT and MWT</article-title>. <source>Sleep</source> <year>2005</year>; <volume>28</volume>: <fpage>123</fpage>–<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr23-1352458511432328">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scaglione</surname><given-names>C</given-names></name>
<name><surname>Vignatelli</surname><given-names>L</given-names></name>
<name><surname>Plazzi</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>REM sleep behaviour disorder in Parkinson’s disease: a questionnaire-based study</article-title>. <source>Neurol Sci</source> <year>2005</year>; <volume>25</volume>: <fpage>316</fpage>–<lpage>321</lpage>.</citation>
</ref>
<ref id="bibr24-1352458511432328">
<label>24.</label>
<citation citation-type="book">
<collab>American Academy of Sleep Medicine</collab>. <source>The International Classification of Sleep Disorders. Diagnostic &amp; Coding Manual</source>. <edition>2nd ed.</edition> <publisher-loc>Westchester, IL</publisher-loc>: <publisher-name>American Academy of Sleep Medicine</publisher-name>, <year>2005</year>.</citation>
</ref>
<ref id="bibr25-1352458511432328">
<label>25.</label>
<citation citation-type="book">
<collab>R Development Core Team</collab> (<year>2008</year>). <source>R: A language and environment for statistical computing</source>. <publisher-name>R Foundation for Statistical Computing</publisher-name>, <year>2008</year>.</citation>
</ref>
<ref id="bibr26-1352458511432328">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tomfohr</surname><given-names>LM</given-names></name>
<name><surname>Ancoli-Israel</surname><given-names>S</given-names></name>
<name><surname>Loredo</surname><given-names>JS</given-names></name>
<name><surname>Dimsdale</surname><given-names>JE</given-names></name>
</person-group>. <article-title>Effects of continuous positive airway pressure on fatigue and sleepiness in patients with obstructive sleep apnea: data from a randomized controlled trial</article-title>. <source>Sleep</source> <year>2011</year>; <volume>34</volume>: <fpage>121</fpage>–<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr27-1352458511432328">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roelcke</surname><given-names>U</given-names></name>
<name><surname>Kappos</surname><given-names>L</given-names></name>
<name><surname>Lechner-Scott</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study</article-title>. <source>Neurology</source> <year>1997</year>; <volume>48</volume>: <fpage>1566</fpage>–<lpage>1571</lpage>.</citation>
</ref>
<ref id="bibr28-1352458511432328">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Inglese</surname><given-names>M</given-names></name>
<name><surname>Park</surname><given-names>SJ</given-names></name>
<name><surname>Johnson</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3 T</article-title>. <source>Arch Neurol</source> <year>2007</year>; <volume>64</volume>: <fpage>196</fpage>–<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr29-1352458511432328">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Macey</surname><given-names>PM</given-names></name>
<name><surname>Henderson</surname><given-names>LA</given-names></name>
<name><surname>Macey</surname><given-names>KE</given-names></name>
<etal/>
</person-group>. <article-title>Brain morphology associated with obstructive sleep apnea</article-title>. <source>Am J Respir Crit Care Med</source> <year>2002</year>; <volume>166</volume>: <fpage>1382</fpage>–<lpage>1387</lpage>.</citation>
</ref>
<ref id="bibr30-1352458511432328">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morrell</surname><given-names>MJ</given-names></name>
<name><surname>McRobbie</surname><given-names>DW</given-names></name>
<name><surname>Quest</surname><given-names>RA</given-names></name>
<name><surname>Cummin</surname><given-names>AR</given-names></name>
<name><surname>Ghiassi</surname><given-names>R</given-names></name>
<name><surname>Corfield</surname><given-names>DR</given-names></name>
</person-group>. <article-title>Changes in brain morphology associated with obstructive sleep apnea</article-title>. <source>Sleep Med</source> <year>2003</year>; <volume>4</volume>: <fpage>451</fpage>–<lpage>454</lpage>.</citation>
</ref>
<ref id="bibr31-1352458511432328">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leocani</surname><given-names>L</given-names></name>
<name><surname>Colombo</surname><given-names>B</given-names></name>
<name><surname>Comi</surname><given-names>G</given-names></name>
</person-group>. <article-title>Physiopathology of fatigue in multiple sclerosis</article-title>. <source>Neurol Sci</source> <year>2008</year>; <volume>29</volume>(<issue>Suppl. 2</issue>): <fpage>S241</fpage>–<lpage>S243</lpage>.</citation>
</ref>
<ref id="bibr32-1352458511432328">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Macey</surname><given-names>KE</given-names></name>
<name><surname>Macey</surname><given-names>PM</given-names></name>
<name><surname>Woo</surname><given-names>MA</given-names></name>
<etal/>
</person-group>. <article-title>Inspiratory loading elicits aberrant fMRI signal changes in obstructive sleep apnea</article-title>. <source>Respir Physiol Neurobiol</source> <year>2006</year>; <volume>151</volume>: <fpage>44</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr33-1352458511432328">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Flachenecker</surname><given-names>P</given-names></name>
<name><surname>Bihler</surname><given-names>I</given-names></name>
<name><surname>Weber</surname><given-names>F</given-names></name>
<name><surname>Gottschalk</surname><given-names>M</given-names></name>
<name><surname>Toyka</surname><given-names>KV</given-names></name>
<name><surname>Rieckmann</surname><given-names>P</given-names></name>
</person-group>. <article-title>Cytokine mRNA expression in patients with multiple sclerosis and fatigue</article-title>. <source>Mult Scler</source> <year>2004</year>; <volume>10</volume>: <fpage>165</fpage>–<lpage>169</lpage>.</citation>
</ref>
<ref id="bibr34-1352458511432328">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gozal</surname><given-names>D</given-names></name>
<name><surname>Kheirandish-Gozal</surname><given-names>L</given-names></name>
</person-group>. <article-title>Cardiovascular morbidity in obstructive sleep apnea: oxidative stress, inflammation, and much more</article-title>. <source>Am J Respir Crit Care Med</source> <year>2008</year>; <volume>177</volume>: <fpage>369</fpage>–<lpage>375</lpage>.</citation>
</ref>
<ref id="bibr35-1352458511432328">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Silverman</surname><given-names>MN</given-names></name>
<name><surname>Heim</surname><given-names>CM</given-names></name>
<name><surname>Nater</surname><given-names>UM</given-names></name>
<name><surname>Marques</surname><given-names>AH</given-names></name>
<name><surname>Sternberg</surname><given-names>EM</given-names></name>
</person-group>. <article-title>Neuroendocrine and immune contributors to fatigue</article-title>. <source>PM R</source> <year>2010</year>; <volume>2</volume>: <fpage>338</fpage>–<lpage>346</lpage>.</citation>
</ref>
<ref id="bibr36-1352458511432328">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carlson</surname><given-names>JT</given-names></name>
<name><surname>Hedner</surname><given-names>J</given-names></name>
<name><surname>Elam</surname><given-names>M</given-names></name>
<name><surname>Ejnell</surname><given-names>H</given-names></name>
<name><surname>Sellgren</surname><given-names>J</given-names></name>
<name><surname>Wallin</surname><given-names>BG</given-names></name>
</person-group>. <article-title>Augmented resting sympathetic activity in awake patients with obstructive sleep apnea</article-title>. <source>Chest</source> <year>1993</year>; <volume>103</volume>: <fpage>1763</fpage>–<lpage>1768</lpage>.</citation>
</ref>
<ref id="bibr37-1352458511432328">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ciftci</surname><given-names>TU</given-names></name>
<name><surname>Kokturk</surname><given-names>O</given-names></name>
<name><surname>Ozkan</surname><given-names>S</given-names></name>
</person-group>. <article-title>Apnea-hypopnea indexes calculated using different hypopnea definitions and their relation to major symptoms</article-title>. <source>Sleep Breath</source> <year>2004</year>; <volume>8</volume>: <fpage>141</fpage>–<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr38-1352458511432328">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Redline</surname><given-names>S</given-names></name>
<name><surname>Kapur</surname><given-names>VK</given-names></name>
<name><surname>Sanders</surname><given-names>MH</given-names></name>
<etal/>
</person-group>. <article-title>Effects of varying approaches for identifying respiratory disturbances on sleep apnea assessment</article-title>. <source>Am J Respir Crit Care Med</source> <year>2000</year>; <volume>161</volume>: <fpage>369</fpage>–<lpage>374</lpage>.</citation>
</ref>
<ref id="bibr39-1352458511432328">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruehland</surname><given-names>WR</given-names></name>
<name><surname>Rochford</surname><given-names>PD</given-names></name>
<name><surname>O’Donoghue</surname><given-names>FJ</given-names></name>
<name><surname>Pierce</surname><given-names>RJ</given-names></name>
<name><surname>Singh</surname><given-names>P</given-names></name>
<name><surname>Thornton</surname><given-names>AT</given-names></name>
</person-group>. <article-title>The new AASM criteria for scoring hypopneas: impact on the apnea hypopnea index</article-title>. <source>Sleep</source> <year>2009</year>; <volume>32</volume>: <fpage>150</fpage>–<lpage>157</lpage>.</citation>
</ref>
<ref id="bibr40-1352458511432328">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Young</surname><given-names>T</given-names></name>
<name><surname>Palta</surname><given-names>M</given-names></name>
<name><surname>Dempsey</surname><given-names>J</given-names></name>
<name><surname>Skatrud</surname><given-names>J</given-names></name>
<name><surname>Weber</surname><given-names>S</given-names></name>
<name><surname>Badr</surname><given-names>S</given-names></name>
</person-group>. <article-title>The occurrence of sleep-disordered breathing among middle-aged adults</article-title>. <source>N Engl J Med</source> <year>1993</year>; <volume>328</volume>: <fpage>1230</fpage>–<lpage>1235</lpage>.</citation>
</ref>
<ref id="bibr41-1352458511432328">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Achiron</surname><given-names>A</given-names></name>
<name><surname>Barak</surname><given-names>Y</given-names></name>
<name><surname>Gabbay</surname><given-names>U</given-names></name>
<etal/>
</person-group>. <article-title>Sleep disturbance in multiple sclerosis:clinical and neuroradiologic correlations related to disease activity</article-title>. <source>J Neuroimmunol</source> <year>1995</year>; <volume>57</volume>(<issue>Suppl. 1</issue>): <fpage>56</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr42-1352458511432328">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tachibana</surname><given-names>N</given-names></name>
<name><surname>Howard</surname><given-names>RS</given-names></name>
<name><surname>Hirsch</surname><given-names>NP</given-names></name>
<name><surname>Miller</surname><given-names>DH</given-names></name>
<name><surname>Moseley</surname><given-names>IF</given-names></name>
<name><surname>Fish</surname><given-names>D</given-names></name>
</person-group>. <article-title>Sleep problems in multiple sclerosis</article-title>. <source>Eur Neurol</source> <year>1994</year>; <volume>34</volume>: <fpage>320</fpage>–<lpage>323</lpage>.</citation>
</ref>
<ref id="bibr43-1352458511432328">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Younes</surname><given-names>M</given-names></name>
</person-group>. <article-title>Role of respiratory control mechanisms in the pathogenesis of obstructive sleep disorders</article-title>. <source>J Appl Physiol</source> <year>2008</year>; <volume>105</volume>: <fpage>1389</fpage>–<lpage>1405</lpage>.</citation>
</ref>
<ref id="bibr44-1352458511432328">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mediano</surname><given-names>O</given-names></name>
<name><surname>Barcelo</surname><given-names>A</given-names></name>
<name><surname>de la Pena</surname><given-names>M</given-names></name>
<name><surname>Gozal</surname><given-names>D</given-names></name>
<name><surname>Agusti</surname><given-names>A</given-names></name>
<name><surname>Barbe</surname><given-names>F</given-names></name>
</person-group>. <article-title>Daytime sleepiness and polysomnographic variables in sleep apnoea patients</article-title>. <source>Eur Respir J</source> <year>2007</year>; <volume>30</volume>: <fpage>110</fpage>–<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr45-1352458511432328">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sauter</surname><given-names>C</given-names></name>
<name><surname>Asenbaum</surname><given-names>S</given-names></name>
<name><surname>Popovic</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Excessive daytime sleepiness in patients suffering from different levels of obstructive sleep apnoea syndrome</article-title>. <source>J Sleep Res</source> <year>2000</year>; <volume>9</volume>: <fpage>293</fpage>–<lpage>301</lpage>.</citation>
</ref>
<ref id="bibr46-1352458511432328">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gottlieb</surname><given-names>DJ</given-names></name>
<name><surname>Whitney</surname><given-names>CW</given-names></name>
<name><surname>Bonekat</surname><given-names>WH</given-names></name>
<etal/>
</person-group>. <article-title>Relation of sleepiness to respiratory disturbance index: the Sleep Heart Health Study</article-title>. <source>Am J Respir Crit Care Med</source> <year>1999</year>; <volume>159</volume>: <fpage>502</fpage>–<lpage>507</lpage>.</citation>
</ref>
<ref id="bibr47-1352458511432328">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McDaid</surname><given-names>C</given-names></name>
<name><surname>Duree</surname><given-names>KH</given-names></name>
<name><surname>Griffin</surname><given-names>SC</given-names></name>
<etal/>
</person-group>. <article-title>A systematic review of continuous positive airway pressure for obstructive sleep apnoea-hypopnoea syndrome</article-title>. <source>Sleep Med Rev</source> <year>2009</year>; <volume>13</volume>: <fpage>427</fpage>–<lpage>436</lpage>.</citation>
</ref>
<ref id="bibr48-1352458511432328">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benbadis</surname><given-names>SR</given-names></name>
<name><surname>Mascha</surname><given-names>E</given-names></name>
<name><surname>Perry</surname><given-names>MC</given-names></name>
<name><surname>Wolgamuth</surname><given-names>BR</given-names></name>
<name><surname>Smolley</surname><given-names>LA</given-names></name>
<name><surname>Dinner</surname><given-names>DS</given-names></name>
</person-group>. <article-title>Association between the Epworth sleepiness scale and the multiple sleep latency test in a clinical population</article-title>. <source>Ann Intern Med</source> <year>1999</year>; <volume>130</volume>: <fpage>289</fpage>–<lpage>292</lpage>.</citation>
</ref>
<ref id="bibr49-1352458511432328">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chervin</surname><given-names>RD</given-names></name>
<name><surname>Aldrich</surname><given-names>MS</given-names></name>
<name><surname>Pickett</surname><given-names>R</given-names></name>
<name><surname>Guilleminault</surname><given-names>C</given-names></name>
</person-group>. <article-title>Comparison of the results of the Epworth Sleepiness Scale and the Multiple Sleep Latency Test</article-title>. <source>J Psychosom Res</source> <year>1997</year>; <volume>42</volume>: <fpage>145</fpage>–<lpage>155</lpage>.</citation>
</ref>
<ref id="bibr50-1352458511432328">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Furuta</surname><given-names>H</given-names></name>
<name><surname>Kaneda</surname><given-names>R</given-names></name>
<name><surname>Kosaka</surname><given-names>K</given-names></name>
<name><surname>Arai</surname><given-names>H</given-names></name>
<name><surname>Sano</surname><given-names>J</given-names></name>
<name><surname>Koshino</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Epworth Sleepiness Scale and sleep studies in patients with obstructive sleep apnea syndrome</article-title>. <source>Psychiatry Clin Neurosci</source> <year>1999</year>; <volume>53</volume>: <fpage>301</fpage>–<lpage>302</lpage>.</citation>
</ref>
<ref id="bibr51-1352458511432328">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Attarian</surname><given-names>HP</given-names></name>
<name><surname>Brown</surname><given-names>KM</given-names></name>
<name><surname>Duntley</surname><given-names>SP</given-names></name>
<name><surname>Carter</surname><given-names>JD</given-names></name>
<name><surname>Cross</surname><given-names>AH</given-names></name>
</person-group>. <article-title>The relationship of sleep disturbances and fatigue in multiple sclerosis</article-title>. <source>Arch Neurol</source> <year>2004</year>; <volume>61</volume>: <fpage>525</fpage>–<lpage>528</lpage>.</citation>
</ref>
<ref id="bibr52-1352458511432328">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newton</surname><given-names>JL</given-names></name>
<name><surname>Gibson</surname><given-names>GJ</given-names></name>
<name><surname>Tomlinson</surname><given-names>M</given-names></name>
<name><surname>Wilton</surname><given-names>K</given-names></name>
<name><surname>Jones</surname><given-names>D</given-names></name>
</person-group>. <article-title>Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence</article-title>. <source>Hepatology</source> <year>2006</year>; <volume>44</volume>: <fpage>91</fpage>–<lpage>98</lpage>.</citation>
</ref>
<ref id="bibr53-1352458511432328">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Valko</surname><given-names>PO</given-names></name>
<name><surname>Bassetti</surname><given-names>CL</given-names></name>
<name><surname>Bloch</surname><given-names>KE</given-names></name>
<name><surname>Held</surname><given-names>U</given-names></name>
<name><surname>Baumann</surname><given-names>CR</given-names></name>
</person-group>. <article-title>Validation of the fatigue severity scale in a Swiss cohort</article-title>. <source>Sleep</source> <year>2008</year>; <volume>31</volume>: <fpage>1601</fpage>–<lpage>1607</lpage>.</citation>
</ref>
<ref id="bibr54-1352458511432328">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bedard</surname><given-names>MA</given-names></name>
<name><surname>Montplaisir</surname><given-names>J</given-names></name>
<name><surname>Richer</surname><given-names>F</given-names></name>
<name><surname>Malo</surname><given-names>J</given-names></name>
</person-group>. <article-title>Nocturnal hypoxemia as a determinant of vigilance impairment in sleep apnea syndrome</article-title>. <source>Chest</source> <year>1991</year>; <volume>100</volume>: <fpage>367</fpage>–<lpage>370</lpage>.</citation>
</ref>
<ref id="bibr55-1352458511432328">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bennett</surname><given-names>LS</given-names></name>
<name><surname>Langford</surname><given-names>BA</given-names></name>
<name><surname>Stradling</surname><given-names>JR</given-names></name>
<name><surname>Davies</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>Sleep fragmentation indices as predictors of daytime sleepiness and nCPAP response in obstructive sleep apnea</article-title>. <source>Am J Respir Crit Care Med</source> <year>1998</year>; <volume>158</volume>: <fpage>778</fpage>–<lpage>786</lpage>.</citation>
</ref>
<ref id="bibr56-1352458511432328">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhan</surname><given-names>G</given-names></name>
<name><surname>Fenik</surname><given-names>P</given-names></name>
<name><surname>Pratico</surname><given-names>D</given-names></name>
<name><surname>Veasey</surname><given-names>SC</given-names></name>
</person-group>. <article-title>Inducible nitric oxide synthase in long-term intermittent hypoxia: hypersomnolence and brain injury</article-title>. <source>Am J Respir Crit Care Med</source> <year>2005</year>; <volume>171</volume>: <fpage>1414</fpage>–<lpage>1420</lpage>.</citation>
</ref>
<ref id="bibr57-1352458511432328">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kronholm</surname><given-names>E</given-names></name>
<name><surname>Hyyppa</surname><given-names>MT</given-names></name>
<name><surname>Alanen</surname><given-names>E</given-names></name>
<name><surname>Halonen</surname><given-names>JP</given-names></name>
<name><surname>Partinen</surname><given-names>M</given-names></name>
</person-group>. <article-title>What does the multiple sleep latency test measure in a community sample?</article-title> <source>Sleep</source> <year>1995</year>; <volume>18</volume>: <fpage>827</fpage>–<lpage>835</lpage>.</citation>
</ref>
<ref id="bibr58-1352458511432328">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kale</surname><given-names>N</given-names></name>
<name><surname>Agaoglu</surname><given-names>J</given-names></name>
<name><surname>Tanik</surname><given-names>O</given-names></name>
</person-group>. <article-title>Neuropsychiatric manifestations in multiple sclerosis: correlation of fatigue and depression with disease progression</article-title>. <source>Neurol Res</source> <year>2010</year>; <volume>32</volume>: <fpage>221</fpage>–<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr59-1352458511432328">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koch</surname><given-names>M</given-names></name>
<name><surname>Mostert</surname><given-names>J</given-names></name>
<name><surname>Heerings</surname><given-names>M</given-names></name>
<name><surname>Uyttenboogaart</surname><given-names>M</given-names></name>
<name><surname>De</surname><given-names>KJ</given-names></name>
</person-group>. <article-title>Fatigue, depression and disability accumulation in multiple sclerosis: a cross-sectional study</article-title>. <source>Eur J Neurol</source> <year>2009</year>; <volume>16</volume>: <fpage>348</fpage>–<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr60-1352458511432328">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patrick</surname><given-names>E</given-names></name>
<name><surname>Christodoulou</surname><given-names>C</given-names></name>
<name><surname>Krupp</surname><given-names>LB</given-names></name>
</person-group>. <article-title>Longitudinal correlates of fatigue in multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2009</year>; <volume>15</volume>: <fpage>258</fpage>–<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr61-1352458511432328">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Penner</surname><given-names>IK</given-names></name>
<name><surname>Bechtel</surname><given-names>N</given-names></name>
<name><surname>Raselli</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Fatigue in multiple sclerosis: relation to depression, physical impairment, personality and action control</article-title>. <source>Mult Scler</source> <year>2007</year>; <volume>13</volume>: <fpage>1161</fpage>–<lpage>1167</lpage>.</citation>
</ref>
<ref id="bibr62-1352458511432328">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Metz</surname><given-names>LM</given-names></name>
<name><surname>Patten</surname><given-names>SB</given-names></name>
<name><surname>Archibald</surname><given-names>CJ</given-names></name>
<etal/>
</person-group>. <article-title>The effect of immunomodulatory treatment on multiple sclerosis fatigue</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>2004</year>; <volume>75</volume>: <fpage>1045</fpage>–<lpage>1047</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>